All News

Stop,pills,water

Can we withdraw treatment in post-menopausal osteoporosis?

d EurekAlert!

Analysis of French claims data, found over half of women initiating oral bisphosphonates (BP) between 2015 and 2020 discontinued treatment for at least one year, which was associated with a 12% increase in fracture risk.

Read Article
RISK OF NON-MELANOMA SKIN CANCER WITH TNFi AND OTHER bDMARDs IN PATIENTS WITH PSORIATIC ARTHRITIS: A SWEDISH AND DANISH COHORT STUDY- despite having minimal sun 25% increase NMSC TNFis vs other bDMARDs - skin checks !@rheumnow #EULAR2024

Peter Nash drpnash ( View Tweet)

steroid dose 120 mg , repeated if not in remission 12 wks on background MTX - no difference between groups @rheumnow #EULAR2024 https://t.co/gkqmElfOCp

Links:

Peter Nash drpnash ( View Tweet)
Deep learning to predict if an #RA patient will benefit from treatment using MRIs abst#0182 Models are still not good for mainstream practice- but will be in the future! Lots of fine tuning required #EULAR2024 #EULARBest @rheumnow https://t.co/9yVN6CHLCv

Links:

Bella Mehta bella_mehta ( View Tweet)
dual IL 17 A & F nanobody typical response at 12 wks not significantly better - how many IL17 inhibs do we need? ⁦@RheumNow⁩ #EULAR2024 https://t.co/50dIKyO0e4

Links:

Peter Nash drpnash ( View Tweet)
Was a full room #EULAR2024 for the SELECT-GCA presentation (upadacitinib in GCA positive study). Palpable excitement through the audience here in Vienna @RheumNow https://t.co/bFL6mqqFAa

Links:

David Liew drdavidliew ( View Tweet)
Using data from a large population > 100 million people with SpA (predominantly PsA) from the TriNetX Global Collaborative Network, JAKi was not associated with increased risk of CVD, VTE or selected cancers, compared to TNFi or IL-17i #EULAR2024 Abstract P0231 @RheumNow https://t.co/Oi64BeWcmk

Links:

Dr. Antoni Chan synovialjoints ( View Tweet)
Patients with r-axSpA can be divided into subgroups with specific pain distribution profiles and sensory symptom profiles (Clusters 1,2,3) 1 with a diffuse distribution of pain over many pain regions indicates activation of the nociplastic pain mechanisms, 2 with pain localised… https://t.co/HsaBzlXzoc https://t.co/CpMPzNWptk

Links:

Dr. Antoni Chan synovialjoints ( View Tweet)
Molecular dissection of OA mechanisms brings some important pieces of knowledge and new potential therapeutic targets GWAS in hands OA #EULAR2024 @RheumNow https://t.co/L7iZgzmFtr

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Get your sunscreen ready 🌞! Higher UV-B exposure asso w/ higher chance of reaching ACR/EULAR Boolean remission in RA pts treated w/ MTX monotherapy Now this could well be a surrogate for other socio demographic factors asso with better prognosis @RheumNow #EULAR2024 OP0153 https://t.co/k852O5psTM

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Nationwide turkish cohort study e.PULSE 347000+ pts Gender based comorbidity analysis Female asso w/ higher -accompanying CTD OR 3.75 -asthma OR 2.06 -depression OR 2.38 -fibromyalgia OR 3.16 and lesser - COPD OR 0.34 - ILD OR 0.60 -Malignancy OR 0.63 @RheumNow #EULAR2024 OP0175

Aurelie Najm AurelieRheumo ( View Tweet)

When to administrate the PCV13 in RA? VACIMRA study 276pts randomized PCV13 + MTX = 75% humoral response PCV13 + MTX 1 month later = 88% humoral response No diff on dis control & GCs or DMARDs use #EULAR2024 @RheumNow AbstOP0140

Aurelie Najm AurelieRheumo ( View Tweet)

#EULARBest @RheumNow https://t.co/cCv88iTCTV

Links:

Aurelie Najm AurelieRheumo ( View Tweet)

ARGO trial Ph 2 RCT Sonelokimab IL-17A/Fi Nanobody Wk 12, primary ACR50 ACR 50 SON 120 mg 46% 60 mg 46% PBO 20% PASI 90 SON 120 mg 60% 60 mg 77% PBO 15% MDA SON 60mg 47% PBO 20% No new safety signal #EULAR2024 @RheumNow AbstrOP0195 https://t.co/4W5KFi23za

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PH 2/3 STUDY OF SHR0302, A SELECTIVE JAK 1 INHIBITOR, IN PATIENTS WITH ACTIVE AS - behaves like a JAK in AxSpA now as well as in RA - safety is clean/no new signals but where is the zoster? @RheumNow #EULAR2024

Peter Nash drpnash ( View Tweet)

Baseline predictors of D2TRA in naive recent onset RA 1000pts -female sex -higher joint count -erosions -pulmonary involvement -depression -fatigue #EULAR24 AbstOP0118 @RheumNow

Aurelie Najm AurelieRheumo ( View Tweet)

COMPARATIVE SAFETY OF JAK INHIBITORS VERSUS TNF OR IL-17 INHIBITORS FOR CARDIOVASCULAR DISEASE, VENOUS THROMBOEMBOLISM AND CANCER IN PSORIATIC ARTHRITIS AND AXIAL - no signal of significant difference but channeling bias last few years @RheumNow #EULAR2024

Peter Nash drpnash ( View Tweet)

COMPARATIVE RISK OF MORTALITY IN NEW USERS OF PRESCRIPTION OPIOIDS FOR NON-CANCER PAIN: RESULTS FROM THE INTERNATIONAL PHARMACOSURVEILLANCE STUDY - HR 9-13 increased deaths narcotic use compared with codeine UK Boston Montreal >1 million pts included @RheumNow #EULAR2024

Peter Nash drpnash ( View Tweet)

3 pain clusters in AxSpA - tres intéressant @RheumNow #EULAR2024 https://t.co/ZgXvsxHlJu

Links:

Peter Nash drpnash ( View Tweet)
OP0202 looks at phenotypes of #RAILD in a cluster analysis 🌎Large multinational cohort 2⃣Two key clusters identified 📈Male sex, older age at RA & ILD onset, European ethnicity, smoking and CCP & RF positivity more frequent in cluster 1 vs 2 @RheumNow #EULAR2024 @Juge_P_A

Mrinalini Dey DrMiniDey ( View Tweet)

×